No connection

Search Results

OKYO vs TCRX

OKYO
OKYO Pharma Limited
BEARISH
Price
$1.65
Market Cap
$86.6M
Sector
Healthcare
AI Confidence
95%
TCRX
TScan Therapeutics, Inc.
BEARISH
Price
$1.43
Market Cap
$85.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
OKYO
--
TCRX
--
Forward P/E
OKYO
-8.25
TCRX
-1.86
P/B Ratio
OKYO
-18.54
TCRX
0.66
P/S Ratio
OKYO
--
TCRX
8.32
EV/EBITDA
OKYO
-9.5
TCRX
-0.18

Profitability

Gross Margin
OKYO
0.0%
TCRX
0.0%
Operating Margin
OKYO
0.0%
TCRX
-851.5%
Profit Margin
OKYO
0.0%
TCRX
0.0%
ROE
OKYO
--
TCRX
-71.28%
ROA
OKYO
-104.63%
TCRX
-27.88%

Growth

Revenue Growth
OKYO
--
TCRX
286.0%
Earnings Growth
OKYO
--
TCRX
--

Financial Health

Debt/Equity
OKYO
--
TCRX
0.76
Current Ratio
OKYO
0.58
TCRX
8.41
Quick Ratio
OKYO
0.53
TCRX
8.15

Dividends

Dividend Yield
OKYO
--
TCRX
--
Payout Ratio
OKYO
0.0%
TCRX
0.0%

AI Verdict

OKYO BEARISH

OKYO exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a critical liquidity position. The company's negative Price/Book ratio (-18.54) and an ROA of -104.63% indicate significant insolvency risk and a lack of tangible asset backing. While analysts maintain a speculative target price of $8.00, the fundamental data reveals a company unable to cover short-term obligations (Current Ratio 0.58) with no current revenue stream. The disconnect between the bullish analyst target and the bearish deterministic health scores suggests a high-risk speculative play rather than a value investment.

Strengths
Significant upside potential if analyst target of $8.00 is realized
Positive 1-year price performance (+47.3%)
Operating in the high-growth Biotechnology sector
Risks
Severe liquidity crisis with a Current Ratio of 0.58
Negative shareholder equity as evidenced by Price/Book of -18.54
Critical financial health (Piotroski F-Score 2/9)
TCRX BEARISH

TCRX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe financial distress across all measured categories. While the company maintains a strong liquidity position with a Current Ratio of 8.41, this is offset by a catastrophic operating margin of -851.50% and a 5-year price decline of 86.4%. The stock is currently a speculative binary play, where a massive disconnect exists between the fundamental health (extremely poor) and analyst price targets ($6.00).

Strengths
Exceptionally high liquidity (Current Ratio 8.41)
Significant YoY revenue growth of 286%
Recent trend of beating EPS estimates (3/4 last quarters)
Risks
Zero Piotroski F-Score indicating systemic financial weakness
Extreme operational inefficiency (Operating Margin -851.50%)
Negative ROE of -71.28% showing rapid equity erosion

Compare Another Pair

OKYO vs TCRX: Head-to-Head Comparison

This page compares OKYO Pharma Limited (OKYO) and TScan Therapeutics, Inc. (TCRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile